Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bcl-2-like protein 10 (BCL2L10), commonly known as Bcl-B, is an anti-apoptotic member of the B-cell lymphoma 2 (Bcl-2) family of proteins. It contains all four Bcl-2 homology (BH) domains (BH1, BH2, BH3, and BH4) and a C-terminal transmembrane domain that anchors it to the outer mitochondrial membrane and endoplasmic reticulum. Bcl-B promotes cell survival by binding to and neutralizing pro-apoptotic proteins such as Bax, Bim, and Bok, thereby preventing mitochondrial outer membrane permeabilization (MOMP) and subsequent caspase activation. In addition to its role in apoptosis, Bcl-B regulates autophagy by interacting with Beclin 1 and modulates calcium homeostasis at the endoplasmic reticulum.\n\nIn pathological contexts, Bcl-B is overexpressed in various malignancies, including lung adenocarcinoma, melanoma, and breast cancer, where its elevated levels correlate with poor prognosis and resistance to chemotherapeutic agents and other BH3 mimetics. Conversely, in some cancers, it may act as a tumor suppressor, highlighting its complex, context-dependent role. Pharmacological targeting of Bcl-B is an active area of oncology research. While broad-spectrum BH3 mimetics like gossypol and gambogic acid inhibit Bcl-B alongside other family members, selective small-molecule inhibitors such as ML258 have been developed to specifically disrupt Bcl-B interactions, offering a potential strategy to sensitize cancer cells to chemotherapy while minimizing the systemic toxicities associated with pan-Bcl-2 inhibition.
Antagonism of anti-apoptotic activity via BH3-mimetic binding, which disrupts the interaction of Bcl-B with pro-apoptotic proteins such as Bax, Bim, and Bok, thereby restoring the intrinsic apoptotic pathway and promoting cell death.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bcl-2-like protein 10 (BCL2L10) (BCL-b).